MediciNova, Inc.
MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophicā¦ read more
Healthcare
Biotechnology
19 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.39
Price+2.21%
$0.03
1Y
Price
Market Cap
$68.418m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1359.2%
EBITDA Margin-1383.2%
Net Profit Margin-1861.7%
Free Cash Flow Margin-1359.2%
EBITDA Margin-1383.2%
Net Profit Margin-1861.7%
Free Cash Flow MarginRevenue
$596.640k
+45.6%
1y CAGR-18.1%
3y CAGR-13.6%
5y CAGREarnings
-$11.720m
+2.3%
1y CAGR-11.7%
3y CAGR+1.0%
5y CAGREPS
-$0.23
+4.2%
1y CAGR-11.8%
3y CAGR+1.5%
5y CAGRBook Value
$39.407m
$42.705m
Assets$3.298m
Liabilities$165.200k
DebtDebt to Assets
0.4%
-
Debt to EBITDAFree Cash Flow
-$9.507m
+3.1%
1y CAGR-10.6%
3y CAGR+2.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company